BR112022014240A2 - Formulação farmacêutica líquida estável, e, kit - Google Patents
Formulação farmacêutica líquida estável, e, kitInfo
- Publication number
- BR112022014240A2 BR112022014240A2 BR112022014240A BR112022014240A BR112022014240A2 BR 112022014240 A2 BR112022014240 A2 BR 112022014240A2 BR 112022014240 A BR112022014240 A BR 112022014240A BR 112022014240 A BR112022014240 A BR 112022014240A BR 112022014240 A2 BR112022014240 A2 BR 112022014240A2
- Authority
- BR
- Brazil
- Prior art keywords
- kit
- pharmaceutical formulation
- stable liquid
- liquid pharmaceutical
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062965786P | 2020-01-24 | 2020-01-24 | |
| PCT/US2021/014524 WO2021150829A1 (en) | 2020-01-24 | 2021-01-22 | Stable antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014240A2 true BR112022014240A2 (pt) | 2022-12-13 |
Family
ID=74858743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014240A BR112022014240A2 (pt) | 2020-01-24 | 2021-01-22 | Formulação farmacêutica líquida estável, e, kit |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12337199B2 (https=) |
| EP (1) | EP4093435A1 (https=) |
| JP (2) | JP7674369B2 (https=) |
| KR (1) | KR20220131923A (https=) |
| CN (1) | CN115243718A (https=) |
| AU (1) | AU2021210942A1 (https=) |
| BR (1) | BR112022014240A2 (https=) |
| CA (1) | CA3162569A1 (https=) |
| CL (2) | CL2022001989A1 (https=) |
| CO (1) | CO2022010254A2 (https=) |
| IL (1) | IL294375B1 (https=) |
| MX (1) | MX2022008949A (https=) |
| WO (1) | WO2021150829A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107635527B (zh) | 2015-03-10 | 2021-04-23 | 里珍纳龙药品有限公司 | 无菌刺穿系统和方法 |
| EP3487521A4 (en) | 2016-07-21 | 2020-07-01 | Emory University | ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM |
| KR102540409B1 (ko) | 2017-05-05 | 2023-06-09 | 리제너론 파아마슈티컬스, 인크. | 자동 주사기 |
| USD1007676S1 (en) | 2021-11-16 | 2023-12-12 | Regeneron Pharmaceuticals, Inc. | Wearable autoinjector |
| TW202529831A (zh) | 2023-10-02 | 2025-08-01 | 美商再生元醫藥公司 | 藥物遞輸裝置安全系統 |
| US12514939B2 (en) | 2024-02-14 | 2026-01-06 | Alpha-9 Oncology, Inc. | Stable radiopharmaceutical compositions and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| US6630144B1 (en) | 1999-08-30 | 2003-10-07 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies to Ebola glycoprotein |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
| WO2009094755A1 (en) | 2008-02-01 | 2009-08-06 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Monoclonal antibodies for ebola and marburg viruses |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| CA2741523C (en) | 2008-10-24 | 2022-06-21 | Jonathan S. Towner | Human ebola virus species and compositions and methods thereof |
| ES2676205T3 (es) * | 2011-03-31 | 2018-07-17 | Merck Sharp & Dohme Corp. | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| JP6041580B2 (ja) * | 2012-08-28 | 2016-12-14 | 京セラ株式会社 | 電子機器、制御方法、及び制御プログラム |
| TWI710573B (zh) * | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TN2017000440A1 (en) | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| JP7402693B2 (ja) * | 2017-05-02 | 2023-12-21 | メルク・シャープ・アンド・ドーム・エルエルシー | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
| KR20210005096A (ko) * | 2018-04-25 | 2021-01-13 | 메디뮨 리미티드 | 인간 항-pd-l1 항체의 제형 |
-
2021
- 2021-01-22 IL IL294375A patent/IL294375B1/en unknown
- 2021-01-22 BR BR112022014240A patent/BR112022014240A2/pt unknown
- 2021-01-22 CA CA3162569A patent/CA3162569A1/en active Pending
- 2021-01-22 KR KR1020227025939A patent/KR20220131923A/ko active Pending
- 2021-01-22 US US17/155,432 patent/US12337199B2/en active Active
- 2021-01-22 WO PCT/US2021/014524 patent/WO2021150829A1/en not_active Ceased
- 2021-01-22 EP EP21710081.7A patent/EP4093435A1/en active Pending
- 2021-01-22 JP JP2022543445A patent/JP7674369B2/ja active Active
- 2021-01-22 MX MX2022008949A patent/MX2022008949A/es unknown
- 2021-01-22 CN CN202180010566.0A patent/CN115243718A/zh active Pending
- 2021-01-22 AU AU2021210942A patent/AU2021210942A1/en active Pending
-
2022
- 2022-07-20 CO CONC2022/0010254A patent/CO2022010254A2/es unknown
- 2022-07-22 CL CL2022001989A patent/CL2022001989A1/es unknown
-
2023
- 2023-08-30 CL CL2023002560A patent/CL2023002560A1/es unknown
-
2025
- 2025-03-10 JP JP2025037025A patent/JP2025090691A/ja active Pending
- 2025-05-20 US US19/213,776 patent/US20250288665A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220131923A (ko) | 2022-09-29 |
| CO2022010254A2 (es) | 2022-08-09 |
| IL294375B1 (en) | 2026-02-01 |
| CN115243718A (zh) | 2022-10-25 |
| JP2023511080A (ja) | 2023-03-16 |
| JP7674369B2 (ja) | 2025-05-09 |
| WO2021150829A1 (en) | 2021-07-29 |
| AU2021210942A1 (en) | 2022-07-14 |
| IL294375A (en) | 2022-08-01 |
| US12337199B2 (en) | 2025-06-24 |
| MX2022008949A (es) | 2022-08-15 |
| JP2025090691A (ja) | 2025-06-17 |
| US20210252146A1 (en) | 2021-08-19 |
| CL2022001989A1 (es) | 2023-03-31 |
| CL2023002560A1 (es) | 2024-03-01 |
| CA3162569A1 (en) | 2021-07-29 |
| EP4093435A1 (en) | 2022-11-30 |
| US20250288665A1 (en) | 2025-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022014240A2 (pt) | Formulação farmacêutica líquida estável, e, kit | |
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| CY1123909T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| JP3058656B2 (ja) | コンタクトレンズ用液剤組成物及びそれを用いたコンタクトレンズの洗浄若しくは保存方法 | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| CO2021016183A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-angptl3 | |
| MX2018014631A (es) | Formulacion de neurotoxina. | |
| BR0014486A (pt) | Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado | |
| CO2021011648A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33 | |
| BR112014030820A2 (pt) | formulação de anticorpos | |
| CO5660273A2 (es) | Formulaciones de proteina y anticuerpo de alta concentracion | |
| CR8904A (es) | Formulaciones estabilizadoras | |
| BRPI0418115A (pt) | formulação lìquida estável de hormÈnio de crescimento | |
| MX2021002935A (es) | Formulacion de anticuerpos contra csf-1r. | |
| BR0308442A (pt) | Composições farmacêuticas sólida e lìquida | |
| CO5150215A1 (es) | Composiciones que tienen estabilidad mejorada | |
| EP3178927B1 (en) | Protein-stabilizing agent and protein-stabilizing method | |
| WO2024073362A3 (en) | Methods and compositions for transport, storage, and delivery of nucleic acids and other molecules | |
| CL2024000401A1 (es) | Formulaciones de anticuerpos | |
| BR112023019096A2 (pt) | Formulações estabilizadas contendo anticorpos biespecíficos anti-muc16 x anti-cd3 | |
| AR131148A1 (es) | Composiciones de insulina de acción rápida (variantes de las mismas) | |
| CL2022003586A1 (es) | Formulaciones de anticuerpo de activina a y métodos para utilizarlas | |
| UY37260A (es) | Formulación de neurotoxina que comprende un tensioactivo, un aminoácido seleccionado de triptófano o tirosina, y un tampón | |
| CO2026000834A2 (es) | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-bcma x anti-cd3 | |
| MX2026001604A (es) | Proteinas modificadas |